Orange Book product · Brand (NDA)
VEPESID
ETOPOSIDE
At a glance
Dec 30, 1986
Approved
Brand (NDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Dec 30, 1986
40 yr 1 mo ago
Today
Pharmaceutical detail
Active ingredient
ETOPOSIDE
Strength
50MG
Dosage form
CAPSULE
Route
ORAL
TE code
AB
Application
NDA 019557
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
No
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 2026AVOPEFBrand (NDA)
NDA 220200 · AVYXA HOLDINGS
- 1983VEPESIDBrand (NDA)
NDA 018768 · CORDEN PHARMA
- 2017ETOPOSIDEGeneric (ANDA)
ANDA 203507 · NATCO PHARMA USA
- 2017ETOPOSIDEGeneric (ANDA)
ANDA 204927 · NATCO PHARMA USA
- 2001ETOPOSIDEGeneric (ANDA)
ANDA 075635 · MYLAN
- 1998ETOPOSIDEGeneric (ANDA)
ANDA 074983 · FRESENIUS KABI USA
- 1998ETOPOSIDEGeneric (ANDA)
ANDA 074968 · WATSON LABS INC
- 1997ETOPOSIDEGeneric (ANDA)
ANDA 074813 · PIERRE FABRE
- 1996ETOPOSIDEGeneric (ANDA)
ANDA 074228 · WATSON LABS
- 1996ETOPOSIDEGeneric (ANDA)
ANDA 074529 · MEITHEAL
- 1996ETOPOSIDEGeneric (ANDA)
ANDA 074513 · ACCORD HLTHCARE
- 1996ETOPOSIDEGeneric (ANDA)
ANDA 074227 · PHARMACHEMIE BV
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
